Tarsus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Tarsus Pharmaceuticals

11/08/2022 22:16

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of 59 cents per share.
    * Revenue fell 30.6% to $15.28 million from a year ago;
analysts
expected $13.00 million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Tarsus Pharmaceuticals Inc shares had risen by 20.2% this
quarter and lost 22.0% so far this year.
    * The company reported a quarterly loss of $5.74 million.
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $53.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 09:16 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.59          -0.24          Beat
 Mar. 31 2022      -0.92          -0.98          Missed
 Dec. 31 2021      -0.73          -0.72          Beat
 Sep. 30 2021      -0.43          -0.76          Missed